L-Histidinol Enhances Cancer Treatment in Mice
Author Information
Author(s): R.C. Warrington, W.D. Fang
Primary Institution: University of Saskatchewan
Hypothesis
Can L-histidinol improve the effectiveness of alkylating agents and daunomycin in treating P388 leukaemia in mice?
Conclusion
L-histidinol significantly improves the efficacy and selectivity of certain cancer drugs, leading to higher survival rates in mice with P388 leukaemia.
Supporting Evidence
- L-histidinol combined with BCNU or cisDDP resulted in 100% cure rates in treated mice.
- Two consecutive treatments with L-histidinol and cyclophosphamide or daunomycin cured over 80% of mice.
- L-histidinol reduced the toxicity of BCNU while enhancing its effectiveness against P388 leukaemia.
Takeaway
L-histidinol helps cancer drugs work better and makes them safer for normal cells, which means more mice with cancer can be cured.
Methodology
DBA/2J mice with P388 leukaemia were treated with L-histidinol and various cancer drugs to assess survival and drug efficacy.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
Female DBA/2J mice, weighing 20-25 g.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website